FDA Expands Johnson & Johnson Ulcerative Colitis Drug Approval To Pediatric Patients

benzinga.com/news/fda/25/10/48107229/fda-expands-johnson-johnson-ulcerative-colitis-drug-approval-to-pediatric-patients

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE:JNJ) Simponi (golimumab) for children with moderately to severely active ulcerative colitis (UC) who weigh at least 15 kg.
The approval is supported by data from the PURSUIT program, which included…

This story appeared on benzinga.com, 2025-10-08 16:57:07.
The Entire Business World on a Single Page. Free to Use →